疏肝健脾方药对非酒精性脂肪性肝病大鼠肝组织LXRαmRNA及蛋白表达的影响（学术论文）.docxVIP

疏肝健脾方药对非酒精性脂肪性肝病大鼠肝组织LXRα mRNA及蛋白表达的影响来源：创新医学网　　作者：杨钦河,王文晶,冯高飞,何秀敏,张玉佩　　作者单位：暨南大学医学院，广东 广州 510632 　　【摘要】目的探讨疏肝健脾方药对非酒精性脂肪性肝病(NAFLD)大鼠肝组织LXRα mRNA及蛋白表达的影响。方法选用SD大鼠55只，随机分为正常组、模型组、疏肝组(灌服3.2 g·kg-1·d-1剂量的柴胡疏肝散)、健脾组(灌服10.0 g·kg-1·d-1剂量的参苓白术散)、综合组(灌服11.9 g·kg-1·d-1剂量的柴胡疏肝散和参苓白术散合方)，模型组15只，其余各组10只。采用灌饲高脂肪乳剂(10 ml/kg)的方法复制大鼠NAFLD实验动物模型，给药8 w后处死动物，腹主动脉采血，用全自动生化分析仪检测血脂及肝功;常规HE染色观察肝组织病理变化;RT-PCR方法检测肝组织LXRα mRNA的表达;免疫组织化学方法检测肝组织LXRα蛋白的表达。结果 与正常组相比，模型组大鼠肝细胞脂肪变性明显，血脂及肝功均有不同程度的升高(P0.05，P0.01)，大鼠肝组织LXRα mRNA及蛋白表达明显升高(P0.01);各给药组血脂及肝功和肝组织LXRα mRNA及蛋白的表达均较模型组显著降低(P0.05，P0.01)，其中以健脾组下降最为明显。结论 疏肝健脾方药对高脂饮食诱导的大鼠NAFLD有较好的治疗作用，其机制可能与其下调肝脏LXRα的表达有关。 　　【关键词】 非酒精性脂肪性肝病;疏肝健脾方药;肝X受体α基因;大鼠 　　【Abstract】 Objective To investigate the effects of soothing liver and invigorating spleen recipes on the expression of LXRα mRNA and protein in hepatic tissue of rats with non-alcoholic fatty liver disease (NAFLD). Methods 55 male SD rats were randomly divided into 5 groups: normal, model, soothing liver (receiving gavage of Chaihu Shugan Powder 3.2 g·kg-1·d-1), invigorating spleen (receiving gavage of Shen Ling Baizhu Powder 10.0 g·kg-1·d-1) and integrated groups (receiving gavage of Chaihu Shugan Powder and Shen Ling Baizhu Powder combination recipes11.9 g·kg-1·d-1). 15 rats were in model group and 10 rats were in each of the other groups. Except the normal group, the rats in other groups were fed with high-fat emulsion by gastric perfusion (10 ml/kg) besides basic diet to induce NAFLD. After treatment for 8 weeks, the rats were executed to obtain blood samples from aortaventralis. The contents of TC, TG, ALT, AST in the serum, as well as TC, TG in the hepatic homogenate were detected by automatic biochemical analyzer. The histopathological changes of hepatic tissue were observed by HE staining. The expression levels of LXRα mRNA in liver tissue were analyzed by reverse transcription polymerase chain reaction (RT-PCR). The expression of protein LXRα in the hepatic tissue was examined by immunohistoc